Supreme Court declines to hear Acorda appeal of adverse Ampyra patent ruling

The U.S. Supreme Court has declined to hear an appeal from Acorda Therapeutics (ACOR +1%) aimed at reviving certain patents covering MS med Ampyra (dalfampridine). In September 2018, the U.S. Court of Appeals for the Federal Circuit voted 2-1 invalidating four of its U.S. patents.

Sales have plummeted since the launch of generic alternatives.

https://seekingalpha.com/news/3504200-supreme-court-declines-hear-acorda-appeal-adverse-ampyra-patent-ruling